An open-label, randomised, parallel group, multicentre study to compare Zoladex [goserelin] 10.8 mg given every 12 weeks with Zoladex 3.6 mg given every 4 weeks in pre-menopausal women with oestrogen receptor positive advanced breast cancer.

Trial Profile

An open-label, randomised, parallel group, multicentre study to compare Zoladex [goserelin] 10.8 mg given every 12 weeks with Zoladex 3.6 mg given every 4 weeks in pre-menopausal women with oestrogen receptor positive advanced breast cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2016

At a glance

  • Drugs Goserelin (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 17 Dec 2009 Status changed from suspended to completed as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top